Brian D. Schnapp
2200 Pennsylvania Avenue NW
Suite 500 West
Washington, DC 20037
Brian represents companies in antitrust litigation and government investigations, focusing on cartel investigations and civil conduct challenges.
Brian has extensive experience representing companies in a full range of criminal and civil competition investigations and global enforcement actions. A key area of Brian’s practice is defending multinational companies in cartel and price-fixing investigations. He also has significant experience defending civil conduct challenges, including abuse of dominance cases, before global competition regulators.
Brian’s experience includes representing clients across a broad range of industries, including technology, automotive, chemical, and agriculture.
Experience Highlights
Representing a U.S. technology company in a series of global competition investigations
Advised clients regarding the antitrust implications of big data and the use of pricing algorithms
Represented a chemical company with global operations in connection with a Department of Justice cartel investigation
Represented a large parts manufacturer in the Department of Justice’s automotive parts investigation and related civil litigation
Credentials
- The George Washington University Law School, J.D. with honors, 2011 (Notes Editor, The George Washington Law Review)
- The George Washington University, B.A., International Affairs magna cum laude, 2006
- Legal 500 U.S., Antitrust: Cartel, 2021 and 2022
- Bloomberg Law, Five Fresh Faces to Know in Antitrust, 2021
- Selected to the Washington, D.C. Rising Stars list, Super Lawyers® (Thomson Reuters), 2018−2021
- Professorial Lecturer in Law, the George Washington University Law School (2016-2017)
- Member: American Bar Association, Section of Antitrust Law
- Maryland
- District of Columbia
- Rankings & AwardsJune 16, 2022
- InsightJanuary 18, 2022
- Rankings & AwardsDecember 8, 2021
- Rankings & AwardsApril 22, 2021
- InsightJanuary 7, 2021
V&E Antitrust Update
- Rankings & AwardsApril 17, 2020
- InsightJanuary 15, 2020
V&E Antitrust Update
- “DOJ’s Catch-22: Corporate Criminal Antitrust Targets Walk A Blurry Line with Culpable Employees,” The Antitrust Source, Vol. 15, Issue 6, August 2016 (co-author)
- “A Prescription for Trouble: Pfizer Hit with FCPA Charges as Focus on Foreign Corruption in the Pharmaceutical Industry Continues,” V&E Foreign Corrupt Practices Act E-communication, August 21, 2012 (co-author)
- “Government in the Director’s Chair? Court Finds Steptoe Not a State Actor in Internal FCPA Investigation,” Ethisphere, July 13, 2012 (co-author)
- “Supreme Court to Decide Important Class Certification Issue Regarding Class-Wide Damages Evidence,” Antitrust News & Notes, July 2012 (co-author)
- “U.S. Supreme Court to Dive Deeply Into Antitrust: Granting Certiorari in Two Antitrust Cases,” V&E Antitrust Updates E-communication, June 27, 2012 (co-author)